CO2019012871A2 - Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida - Google Patents
Métodos de cultivo celular para expresar proteínas con heterogeneidad reducidaInfo
- Publication number
- CO2019012871A2 CO2019012871A2 CONC2019/0012871A CO2019012871A CO2019012871A2 CO 2019012871 A2 CO2019012871 A2 CO 2019012871A2 CO 2019012871 A CO2019012871 A CO 2019012871A CO 2019012871 A2 CO2019012871 A2 CO 2019012871A2
- Authority
- CO
- Colombia
- Prior art keywords
- cell culture
- culture methods
- express proteins
- heterogeneity
- reduced heterogeneity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1708655.4A GB201708655D0 (en) | 2017-05-31 | 2017-05-31 | Cell culture methods |
| PCT/EP2018/064102 WO2018219968A1 (en) | 2017-05-31 | 2018-05-29 | Cell culture methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019012871A2 true CO2019012871A2 (es) | 2020-01-17 |
Family
ID=59270991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0012871A CO2019012871A2 (es) | 2017-05-31 | 2019-11-18 | Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12077796B2 (https=) |
| EP (2) | EP4397682A3 (https=) |
| JP (3) | JP7460370B2 (https=) |
| KR (3) | KR20240096888A (https=) |
| CN (2) | CN110741077B (https=) |
| AU (2) | AU2018276376C1 (https=) |
| BR (1) | BR112019024390A2 (https=) |
| CA (1) | CA3065661A1 (https=) |
| CL (1) | CL2019003459A1 (https=) |
| CO (1) | CO2019012871A2 (https=) |
| EA (1) | EA201992828A1 (https=) |
| ES (1) | ES2978394T3 (https=) |
| GB (1) | GB201708655D0 (https=) |
| HR (1) | HRP20240585T1 (https=) |
| HU (1) | HUE066922T2 (https=) |
| IL (2) | IL270880B2 (https=) |
| MX (1) | MX2019014140A (https=) |
| MY (1) | MY193535A (https=) |
| PL (1) | PL3630946T3 (https=) |
| RU (2) | RU2021128024A (https=) |
| WO (1) | WO2018219968A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| JP2023554489A (ja) * | 2020-12-22 | 2023-12-27 | ノバルティス アーゲー | 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法 |
| GB202105424D0 (en) * | 2021-04-16 | 2021-06-02 | UCB Biopharma SRL | Cell culture processes |
| WO2025262319A1 (en) | 2024-06-21 | 2025-12-26 | Boehringer Ingelheim International Gmbh | Modifying blue color formation in bioprocesses |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP1482031B1 (en) | 1996-08-30 | 2015-10-28 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| ATE472597T2 (de) | 2003-05-15 | 2010-07-15 | Wyeth Llc | Kontrollierte glukosezufuhr für tierzellkultur |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| ES2538986T3 (es) * | 2006-11-08 | 2015-06-25 | Wyeth Llc | Medios diseñados racionalmente para un cultivo celular |
| US8030027B2 (en) * | 2008-04-29 | 2011-10-04 | St. Jude Children's Research Hospital | Method for enhancing recombinant antibody production |
| US8252557B2 (en) | 2008-10-28 | 2012-08-28 | Chugai Seiyaku Kabushiki Kaisha | Peptide-containing culture medium for culturing animal cell |
| US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
| SG185037A1 (en) | 2010-04-26 | 2012-11-29 | Novartis Ag | Improved cell culture medium |
| AU2011246502B2 (en) | 2010-04-26 | 2014-08-28 | Novartis Ag | Improved cell cultivation process |
| CN102653729B (zh) | 2011-03-04 | 2014-07-16 | 上海赛金生物医药有限公司 | 一种用于中国仓鼠卵巢细胞的培养基 |
| WO2012145682A1 (en) * | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| JP6265970B2 (ja) * | 2012-03-26 | 2018-01-24 | サノフイ | 安定なＩｇＧ４に基づく結合剤の製剤 |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| EP2968544A4 (en) * | 2013-03-15 | 2016-10-12 | Hoffmann La Roche | CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY |
| BR112016027797A2 (pt) | 2014-06-18 | 2017-10-31 | Medimmune Llc | métodos e meios de cultura de células compreendendo n-acetilcisteína |
| WO2016108765A1 (en) | 2014-12-29 | 2016-07-07 | Wirojpaisi Wanlop | Engine combustion system oxygen efficiency enhancing device with raised electrical voltage and improved installation method |
| GB201508180D0 (en) * | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| US11220668B2 (en) * | 2016-04-28 | 2022-01-11 | Merck Patent Gmbh | Method for reducing the trisulfide level in proteins |
| GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| CN106222129A (zh) | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| WO2018018613A1 (zh) * | 2016-07-29 | 2018-02-01 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
-
2017
- 2017-05-31 GB GBGB1708655.4A patent/GB201708655D0/en not_active Ceased
-
2018
- 2018-05-29 KR KR1020247019609A patent/KR20240096888A/ko active Pending
- 2018-05-29 MX MX2019014140A patent/MX2019014140A/es unknown
- 2018-05-29 KR KR1020257034169A patent/KR20250156183A/ko active Pending
- 2018-05-29 EA EA201992828A patent/EA201992828A1/ru unknown
- 2018-05-29 US US16/615,419 patent/US12077796B2/en active Active
- 2018-05-29 CA CA3065661A patent/CA3065661A1/en active Pending
- 2018-05-29 RU RU2021128024A patent/RU2021128024A/ru unknown
- 2018-05-29 BR BR112019024390-9A patent/BR112019024390A2/pt unknown
- 2018-05-29 HU HUE18743683A patent/HUE066922T2/hu unknown
- 2018-05-29 AU AU2018276376A patent/AU2018276376C1/en active Active
- 2018-05-29 JP JP2019566198A patent/JP7460370B2/ja active Active
- 2018-05-29 EP EP24164969.8A patent/EP4397682A3/en active Pending
- 2018-05-29 PL PL18743683.7T patent/PL3630946T3/pl unknown
- 2018-05-29 ES ES18743683T patent/ES2978394T3/es active Active
- 2018-05-29 IL IL270880A patent/IL270880B2/en unknown
- 2018-05-29 HR HRP20240585TT patent/HRP20240585T1/hr unknown
- 2018-05-29 CN CN201880035870.9A patent/CN110741077B/zh active Active
- 2018-05-29 MY MYPI2019006875A patent/MY193535A/en unknown
- 2018-05-29 CN CN202411456463.9A patent/CN119326882A/zh active Pending
- 2018-05-29 EP EP18743683.7A patent/EP3630946B1/en not_active Revoked
- 2018-05-29 IL IL317828A patent/IL317828A/en unknown
- 2018-05-29 WO PCT/EP2018/064102 patent/WO2018219968A1/en not_active Ceased
- 2018-05-29 KR KR1020197038895A patent/KR20200012972A/ko not_active Ceased
- 2018-05-29 RU RU2019143742A patent/RU2758674C2/ru active
-
2019
- 2019-11-18 CO CONC2019/0012871A patent/CO2019012871A2/es unknown
- 2019-11-26 CL CL2019003459A patent/CL2019003459A1/es unknown
-
2021
- 2021-08-31 JP JP2021141016A patent/JP7560420B2/ja active Active
-
2022
- 2022-07-06 JP JP2022109106A patent/JP7406593B2/ja active Active
-
2024
- 2024-08-23 US US18/813,117 patent/US20250051824A1/en active Pending
- 2024-11-11 AU AU2024259881A patent/AU2024259881B2/en active Active
- 2024-11-15 US US18/948,600 patent/US20250066832A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012871A2 (es) | Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida | |
| CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
| AR094375A1 (es) | Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular | |
| EA201890137A1 (ru) | Среда для культивирования клеток с добавлением таурина и способы применения | |
| MX2018003144A (es) | Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas. | |
| CY1122612T1 (el) | Μεθοδος | |
| MX384960B (es) | Cultivo celular metabolicamente optimizado | |
| MX2017005344A (es) | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. | |
| MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
| EA201692025A1 (ru) | Доставка белков, осуществляемая на основе бактерий | |
| MX2018013081A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
| EA201791275A1 (ru) | Способы получения ctp-модифицированных полипептидов длительного действия | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| MX2020001223A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| EA201591832A1 (ru) | Коэкспрессия фактора viii и фактора фон виллебранда | |
| MX2021001981A (es) | Metodos para preparar un poloxamero para usar en medio de cultivo celular. | |
| MX374934B (es) | Marcador de seleccion novedoso para transfeccion celular y produccion de proteinas. | |
| MX2016013955A (es) | Drimenol-sintasas y metodo de produccion de drimenol. | |
| AR112851A1 (es) | Procedimiento para la obtención de una glicoproteína con un mayor porcentaje de glicanos afucosilados | |
| MX2024002130A (es) | Metodos y composiciones para mejorar la expresion de proteinas recombinantes. | |
| AR094875A1 (es) | Formulaciones y procedimientos para la producción de proteína recombinante aumentada | |
| MX2018013683A (es) | Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos. | |
| RU2014131397A (ru) | Крылатая ракета, в частности - противокорабельная (варианты) |